Rare disease specialist Alexion Pharmaceuticals has announced it will be establishing a new global headquarters in its old hometown of New Haven, Connecticut. The 9-floor headquarters will house a state-of-the-art laboratory and office building, and Alexion says the development marks a milestone in the expansion of the company’s research and business operations. The Soliris manufacturer plans to move 400 employees into the headquarters when the company takes occupancy in 2015.
“Our new global headquarters will support our continued growth as we work to develop and deliver life-transforming therapies for patients with severe and life-threatening disorders that are also ultra-rare,” said Leonard Bell, MD, Chief Executive Officer of Alexion. “We are especially pleased by this step because our return to New Haven is a homecoming for our company, and we are able to take part in the redevelopment of the downtown area.”
The Motley Fool listed Connecticut as the 4th richest state in America, naming Alexion as being at the forefront of Connecticut’s innovative edge.
If you want to know more about innovation and strategy in the orphan drug market, you might be interested in attending the 4th World Orphan Drug Congress Europe, Geneva, 14th November 2013, where Martin Mackay, Alexion’s EVP & Global Head of R&D will be presenting on ‘How to successfully develop and commercialise an orphan product’.